| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | 0.08 | 0.03 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.11 | 0.03 |
| mRNA | 681640 | GDSC1000 | pan-cancer | AAC | -0.082 | 0.03 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.074 | 0.03 |
| mRNA | HC-067047 | CTRPv2 | pan-cancer | AAC | 0.079 | 0.03 |
| mRNA | UNC0638 | CTRPv2 | pan-cancer | AAC | 0.075 | 0.03 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.065 | 0.03 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | -0.076 | 0.04 |
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | 0.075 | 0.04 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | 0.077 | 0.04 |